Viewing Company CRH Medical Corp. | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

CRH Medical Corp. Stock Symbol: CRH-T

Last Price Recorded: $9.1300 on 2017-04-24

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-04-11 PARTIAL BUY Ryan Modesto

He likes this. A bit of a rollup. They are buying portions of medical practices in the US, and then are installing anaesthesiologists to do anaesthetic services. The valuation is running up a bit, but if you are looking at Enterprise Value to a bit of multiple, it is about 16X. Still a bit pricey, but nothing too crazy. He likes that they are offering liquidity to doctors, who are starting to age and want to get some cash out of the business. Good insider ownership. Worth owning, but you might want to average into it.


Price:
$12.030
Subject:
CANADIAN SMALL & MIDCAPS
Bias:
UNKNOWN
Owned:
No
2017-04-03 BUY Keith Richards

It is your classic breakout.  It is just pulling back now and then will continue back up.  It is a very bullish chart.


Price:
$10.920
Subject:
TECHNICAL ANALYSIS
Bias:
BULLISH on ENERGY
Owned:
Unknown
2017-03-13 COMMENT Matt Kacur

A very strong company. ROC is astoundingly high. The valuation looks really good. From a pure, financial Return on Capital and valuation perspective, this looks really good.


Price:
$10.720
Subject:
NORTH AMERICAN
Bias:
CAUTIOUS
Owned:
Unknown
2017-03-10 BUY on WEAKNESS Bruce Campbell (2)

Doesn’t think they will need to do an equity raise unless they do a big acquisition. They roughly have the cash flow they need to make an acquisition each quarter, of about the same size that they have been doing. His one caution is that the valuation is very high. Be prepared that an analyst could come out and say it is fully valued, resulting in the stock pulling back. If it did, it would probably be a great buying opportunity. Also, if they did an equity offering, that would be another great time to add to your holdings.


Price:
$10.380
Subject:
CANADIAN & CANNABIS STOCKS
Bias:
OPTIMISTIC
Owned:
Unknown
2017-02-28 HOLD Peter Imhof

Involved with gastrointestinal, and they work with anesthesia to provide for colonoscopies, etc. They’ve been trying to consolidate the market. Just reported a blowout quarter and the stock moved up quite a bit. Management has done a great job of under promising and over delivering.


Price:
$9.190
Subject:
NORTH AMERICAN - SMALL
Bias:
UNKNOWN
Owned:
Yes
2017-02-22 HOLD Jerome Hass

This tends to be a serial acquirer, and he generally doesn’t like these. However, in this case he likes management and feels they are very competent.


Price:
$8.570
Subject:
CANADIAN MID-CAPS & LONG/SHORT STRATEGIES
Bias:
CAUTIOUS
Owned:
No
2017-01-24 BUY Jason Del Vicario

Has done tremendously well. Broke out of a trading range at about $5.50 on heavy volume. It has a high cash ROE and a relatively low P/E ratio. Feels they are getting to be more well known, but they don’t have a wide analyst following, which he would like to see. Expects the stock price to consolidate at around the $7.50-$8.50 level. Assuming they can continue to grow their earnings and add more facilities to their portfolio, the stock certainly has room to run. Represents decent value at these levels.


Price:
$7.990
Subject:
NORTH AMERICAN (GROWTH)
Bias:
CAUTIOUSLY OPTIMISTIC
Owned:
Yes
2017-01-06 BUY Matt Kacur

ROC on this is tremendous. He has it as 104%, which is almost unheard of. Also, it looks undervalued.


Price:
$7.810
Subject:
NORTH AMERICAN
Bias:
BULLISH
Owned:
Unknown
2017-01-03 COMMENT Elliot Fishman

Technically, this looks fantastic. On any medical type stocks, you go with the wave. Right now the wave is up, and if he had to Buy or Sell it, he would buy.


Price:
$7.250
Subject:
TECHNICAL ANALYSIS
Bias:
CAUTIOUS
Owned:
Unknown
2016-12-20 BUY Peter Imhof

It is a buy or a hold.  He is one of the largest holders.  This has been a top pick of his.  It is a health care company, the top performing one in Canada this year.  They did a very good job at increasing their earnings.  Last quarter the stock took off.  A lot more small cap managers are looking at it now.  He likes the management team from a previous company.


Price:
$7.060
Subject:
NORTH AMERICAN - SMALL
Bias:
SELECTIVE
Owned:
Yes
2016-12-05 SELL Alex Ruus

A good little Canadian medical story. Operates primarily in the US, and has been rolling up some healthcare services. He is cautious in this area right now. The US health business is pretty complicated right now, as there are a bunch of pieces to it, unlike the Canadian system. One segment of this company has a fair bit of “off network” business, which pays much better than being paid by Medicare and Medicaid, but sometimes it is hard to get paid, as insurers take their time. Companies like this could be under a bit of pressure next year, so he would be cautious. At this point he wouldn’t be owning it.


Price:
$7.530
Subject:
NORTH AMERICAN
Bias:
OPTIMISTIC
Owned:
No
2016-11-16 TOP PICK Bruce Campbell (2)

This continues to grow by acquisition. They have 2 different product lines, but the anaesthesiology side is where they are really starting to grow. Generating between $5-$6 million in cash flow per quarter, along with a line that allows them to continue to make acquisitions. They’ve been pretty disciplined about how they have done this. (Analysts’ price target is $7.52.)


Price:
$7.390
Subject:
CANADIAN
Bias:
BULLISH
Owned:
Yes
2016-10-26 COMMENT Bruce Campbell (2)

The company is not going to be out raising money, but are going to be doing smaller tuck in acquisitions. They are in the acquisition business. If they have the cash flow to fund an acquisition, they will be fine, but if not and it is something bigger, they’ll probably have to go to the market.


Price:
$6.210
Subject:
CANADIAN
Bias:
UNKNOWN
Owned:
Yes
2016-10-20 HOLD Jason Del Vicario

This has spent the last 18 months consolidating, and has just recently broke out of a trading range at around the $5.40-$5.50 level. He sees a lot of upside in this. A very well-run company. Their cash ROE is north of 30%, and their cash P/E ratio is at around 10 or 11.


Price:
$6.140
Subject:
NORTH AMERICAN (GROWTH)
Bias:
UNKNOWN
Owned:
Yes
2016-09-29 HOLD Peter Imhof

He really likes the management team.  He continues to hold it although the whole healthcare sector has been under scrutiny.  Their earnings have grown as they made tuck-in acquisitions.  They recently did some marketing.  Over the next couple of years earnings estimates should go up.


Price:
$5.110
Subject:
NORTH AMERICAN - SMALL
Bias:
BULLISH on SMALL CAPS
Owned:
Yes
Showing 1 to 15 of 58 entries
<< < 1 2 3 4 > >>

No Comments.


You must be logged in to comment.